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INTRODUCTION
Transthyretin (TTR) is a soluble plasmatic transporter of thyroxine and retinol-binding protein. It presents a native tetrameric structure that, in the presence of an amyloidogenic mutation, is more unstable and prone to dissociation into monomers. These are susceptible to misfolding and self-aggregation in insoluble amyloid fibrils capable of systemic extracellular deposition [1, 2] . Usually amyloidosis is not evident until adulthood, probably reflecting the influence of non-genetic factors, such as those associated with the ageing process [3] . There is a greater susceptibility to fibrinogen glycation, impairing its chaperone activity and therefore the TTR tetramer stability [4] . To date, more than 120 mutations of the single gene encoding TTR are described in the literature [2, 3] and approximately 13 are non-amyloidogenic [5, 6] .
The disease phenotype is variable according to the genotype, although a clear genotypic/phenotypic relationship is absent [1, 6] . The worldwide most common mutation, TTR V30M -substitution of methionine for valine at position 30, has main foci in Portugal, Sweden and Japan [1, 7] . It predominantly gives rise to an autosomal-dominant neuropathy first described by Corino de Andrade as Portuguese type Familial Amyloidotic Polyneuropathy (TTR-FAP) [6, 8] . This sensorimotor polyneuropathy usually begins with sensitive disorders in the lower extremities, like dissociated anesthesia and paresthesia, which show an upward progression. The autonomic involvement also manifests early, by gastrointestinal disturbances, orthostatic hypotension, neurogenic bladder or erectile dysfunction. Motor dysfunction commonly occurs within a few years [1, 8] . Although, other organs such as heart, gastrointestinal tract and kidneys can be affected, demonstrating the disease systemic nature [1, 6] . TTR-FAP relentlessly progresses and becomes extremely disabling, with patients losing their walking capacity, experiencing malnutrition, life-threatening autonomic dysfunction and finally death [6] . Familial Amyloidotic Cardiomyopathy is another relatively common phenotype of hereditary TTR amyloidosis (ATTR), characterized by an infiltrative cardiomyopathy with involvement of the conduction system, and usually associates with some non-TTR V30M mutations [1, 3, 7] .
The diagnosis is based on identification of TTR mutation, suggestive clinical picture and histological evidence of TTR amyloid deposits, since ATTR has incomplete penetrance. The definitive diagnosis is established by tissue biopsy, however this has a significant risk of falsenegative outcomes owing to the patchy pattern of amyloid deposition [1, 6] . In non-endemic areas the diagnosis can be even more difficult once the ATTR generally manifests without familial antecedents [1, 6, 7] and possibly by atypical features like ataxia or upper limb onset neuropathy [9] . Distinct geographic groups vary in penetrance, age at onset, symptoms and survival, even for the same TTR mutation [1, 2, 6] . Early-onset ATTR V30M usually occurs in 3 Portuguese and Japanese patients around the third decade of life; onset in the fifth decade is typical in Swedish cases. The bimodal age at onset may be correlated with the composition of TTR fibrils [2, 6, 10] and the presence of anti-TTR V30M antibodies [9] .
Liver transplantation suppresses the production of circulating mutant TTR and theoretically stops the amyloid formation and disease progression, since most of TTR has hepatic origin [2, 6] . Epithelial cells of the choroid plexus and the retinal pigment epithelium also express TTR. Therefore, several genotypes may have leptomeningeal and ocular involvement like vitreous opacities, probably due to locally produced TTR [1, 3] .
In this review, we focus the current knowledge about orthotopic liver transplantation (OLT). It also addresses combined liver-heart/kidney transplantation, the controversies around sequential liver transplantation and novel therapeutic approaches for ATTR.
ORTHOTOPIC LIVER TRANSPLANTATION FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS

Historical Perspective
The inaugural OLT for ATTR was performed in 1990 [11] . Previously the disease management was based only in symptomatic treatment without any improvement in overall survival. Thus, OLT was expected to be a disease-modifying and curative procedure [1, 12] .
By the time of the first Workshop in Liver Transplantation for FAP (1993), OLT became an accepted treatment for TTR-FAP, since the outcomes were encouraging [11, 13] 
Prognostic predictors after orthotopic liver transplantation
After 23 years of cumulative experience is consensual that the major prognostic factors are:
Age at liver transplantation -advanced age is an independent risk factor for late mortality [14] [15] [16] [17] . Late-onset disease tends to be associated with lower post-transplant survival [18] and with progressive cardiomyopathy, especially in males with TTR V30M [19] . This seems to be related with age-dependent modifications in extracellular matrix components and deposition of a different type of amyloid fibrils [20] .
Duration of disease -OLT performed in long-standing disease (≥7 years) is associated with inferior survival and quality of life (QOL) [6, 17, [21] [22] [23] [24] [25] .
Pre-transplant clinical status -peripheral neuropathy does not seem to be correlated with mortality [14, 26, 27] . It has main impact in QOL since the pre-transplant symptoms usually do not regress significantly [5, 6, 28] . Autonomic dysfunction however increases the surgical risk 4 due to intraoperative circulatory instability and may be associated with late sudden death, probably potentiated by life-threatening arrhythmias [6, 14, 29, 30] . In Portuguese type patients, myocardial sympathetic denervation assessed by 123-iodine metaiodobenzylguanidine ( 123 I-MIBG) imaging is an independent prognostic predictor. Late heart-to-mediastinum 123 I-MIBG uptake ratio <1.60 is associated with higher neurological disability and mortality, although they apparently still benefit from OLT [31] . Okamoto et al. [32] propose a possible correlation between pre-transplant cardiomyopathy and post-transplant survival, with 10-years survival rates of 92% and 64%, respectively for patients without and with cardiomyopathy.
Preoperative nutritional status -severe malnutrition is associated with higher mortality and OLT does not improve the prognosis [22] . Modified body mass index (mBMI) is remarkable in predicting post-transplant morbidity and survival that is better in patients with mBMI >600, compared to patients not undergoing OLT [18] . mBMI shows a strong correlation with duration of disease and, as an objective measure, allows more accurately survival comparisons [14] .
Type of transthyretin mutation -OLT performed for/in non-TTR V30M cases is associated with lower 5-year survival rate [33] . There are also several records of amyloidosis progression in these patients [19, 30, 34, 35] .
Composition of transthyretin fibrils -patients with a mixture of truncated and full-length TTR (type A) appear to be more prone to post-transplant development or progression of cardiomyopathy and heart failure, compared to the ones with type B fibrils (only full-length TTR). Hereafter, this histopathological criterion can assume a relevant role in patient selection [36] .
Despite all of these predictive factors for OLT outcomes and their importance in optimizing patient selection, establish the prognosis for a specific patient is still a challenge.
Indications and timing of referral for orthotopic liver transplantation
Patients with symptomatic TTR-FAP are the most common candidates for OLT.
Asymptomatic carriers have no indication to OLT, since they may never develop the disease [1, 6, 29] . Mildly symptomatic patients may be deprived of living a few years with good QOL when submitted to OLT since it implies specific cares, like immunosuppression [18] .
After clinical stabilization with symptomatic treatment, a selection of transplant candidates should be done according to the prognostic factors mentioned [1] . Suhr et al. [29] defined some unsuitable candidates for OLT -patients with severe neuropathy, particularly if they have hand dysfunction or pronounced risk for circulatory instability; cases of cardiomyopathy with late-onset or in elderly, especially if male, or in patients with type A fibrils; patients with long-standing disease and mBMI <600. Moreover, OLT seems to be an inadequate treatment for patients with an oculoleptomeningeal phenotype [37] [38] [39] .
To optimize post-transplant survival and QOL, the referral for OLT should be done immediately after the diagnosis establishment and ideally in initial phases of the disease, particularly stage I (walking unaided) and sometimes early stage II disease (walking with assistance) [1, 6, [21] [22] [23] [24] 40] . However, the challenge of early diagnosis and the prolonged waiting time on the transplant list, can be an obstacle to this goal. Besides that, the rate of symptomatic progression is unpredictable due to high inter-individual variability [1, 6, 14] .
Outcomes of orthotopic liver transplantation
Overall patient survival rate: Natural average life expectancy is 9-13 years after the symptomatic presentation and death usually is secondary to cardiac involvement or cachexia [6, 10] . The value of OLT in prolonging survival beyond that expected from the natural course of ATTR was demonstrated [16, 41] . Five-year survival figures evolved from 78% in 2001 [42] to more than 90% [29] or even 100% [7] at experienced centers. Additionally there are more reports of excellent survival with a 10-year survival estimated probability of 100% compared to 56,1% in non-transplanted patients [41] . These results are probably the reflection of accumulated experience, better patient selection, earlier referral to OLT, recognition of the peculiarity of these patients, prevention and management of intraoperative and posttransplant specific complications [14, 17] . However, these statistics are mostly related to patients with ATTR V30M. According to FAPWTR [33] , the 5-year survival rate was 59% for non-ATTR V30M patients against 82% for V30M.
Clinicopathological outcomes:
Early experience suggested symptomatic improvement as the rule [13, 21, 43, 44] , but nowadays it is consensual that the natural steadily clinical deterioration is halted in most of transplanted patients. Therefore, main pre-transplant symptoms will still be present after transplantation [14, 17, 24, 35, 40, 45, 46] . Although some patients may manifest symptomatic improvement or deterioration [12, 17, 29, 47] . The latter is most likely in patients presenting poor prognostic factors [12] . Results vary in accordance with the specific symptoms evaluated (table 1) , like cardiovascular manifestations that tend to progress [30] . It has been hypothesized that there is a point of progression of the disease from which there are no regression, possibly because of irreversible organ injury, reinforcing the need for early transplantation [1, 35, 48] .
After OLT, mutant TTR is rapidly cleared from circulation [11] , since it has a brief plasma half-life (2.1 days) [44] and there is no consistent evidence that extra-hepatic sources of TTR contribute to its plasmatic pool [2] . Regression of visceral amyloid deposits, evidenced by serum amyloid P component scintigraphy and acompained by symptomatic improvement, was seen in 2 of the first transplanted patients [13] , but without histological evidence of it. In a series of 6 transplanted patients with ATTR V30M, all showed reduction or disappearance of amyloid deposits in sequential abdominal fat aspirates more than 10 years after OLT, even in a patient with disease progression [47] . Remains the question regarding which is the amyloid status of the main target organs. Currently it is believed that the most probable posttransplant outcome is no significant reduction of amyloid deposits [1, 45, 49] , with some reports of ongoing amyloid deposition, essentially at cardiac tissue ( Figure 1 ) and in cases of non-ATTR V30M [12, 19, 24, 30, 34, [50] [51] [52] . Although less significant, there may be amyloidosis progression in other organs [52] ( Table 1) .
As evidenced by senile systemic amyloidosis, an age-related TTR amyloidosis predominantly manifested by cardiomyopathy, wild-type TTR is capable of amyloid deposition, demonstrating an inherent amyloidogenic capacity [2, 6, 10, 35] . Thus, amyloidogenesis can persist even in the absence of mutant TTR, apparently by deposition of wild-type TTR on a substrate of pre-existing amyloid fibrils [2, 6, 47, 53] , especially with type A fibrils [36] .
Opposite to end-stage liver disease, the post-transplant improvement is less recognizable in patients with ATTR since they usually have fewer pre-transplant symptoms and this major surgery does not guarantee their regression. The patient must be advised that the aim of OLT is prevent additional deterioration and new complications [6, 17, 48] .
Quality of life:
As this is a progressively disabling disease, the goal of OLT goes beyond the mortality reduction. However, this has fallen short of expectations when comparing to liver transplanted patients for other causes, probably due to post-transplant persistence of symptoms [54, 55] .
Cause of death:
In the OLT era, death from cardiac disease acquired greater representation comparatively to historical causes of death like cachexia, infections or cardiovascular collapse [8] . Recent data from FAPWTR points out for 45% of post-transplant deaths from cardiac causes or septicemia. To prevent this outcome, post-transplant follow-up of all ATTR cases, especially in aging patients due to their greater risk for cardiomyopathy progression, must include a periodic echocardiogram and Holter ECG [17, 35, 38, 51] . Okamoto et al. [56] also proposed serial evaluations of serum BNP. ATTR patients are more susceptible to early post-transplant thrombotic complications, in particular to hepatic artery thrombosis that correlates with high morbidity [57] .
Sequential Liver Transplantation
Also known as domino liver transplantation (DLT), it consists in transplanting the explanted ATTR liver into a selected non-ATTR patient. This is feasible since ATTR gathers the essential conditions: the liver is anatomically and functionally normal, despite being the major source of mutant TTR, with scarce amyloid deposits and circumscribed to portal vessels and hilar nerves (Figure 2 ) [58] ; has a long latent time before the clinical onset, at least 20 years [59] . Furthermore, as a living graft, the ischemic time is very short and thus the likelihood of graft dysfunction decreases [60] .
It was first performed in 1995 in Portugal, by Furtado et al. [59] , in order to face the disproportionate supply of deceased organ donors and the rising waiting list for OLT. The initial DLT recipients were patients with unresectable primary or metastatic liver cancers, with no extrahepatic spread and short life expectancy. The safety and successful short-term results for both DLT donors and recipients allowed a worldwide acceptance [59] [60] [61] . The last update of Domino Liver Transplant Registry (DLTR) displays a total of 1085 DLT performed, with ATTR patients as the main donors.
However, the main pitfall of DLT is the risk of the recipient develops de novo ATTR, since circulating mutant TTR is soon after detected. Thus the need for a close follow-up with monitorization of clinical signs was early recognized [58, 59, 61] .
Despite the hope that the disease would take at least 30 years to develop, based on the natural history of ATTR [59] , the first report of symptomatic systemic TTR amyloidosis in a DLT recipient occurred after 8 years of follow-up [62] . However, subclinical skin and nerve amyloid deposits were found 3 and 6 years after DLT, respectively [63] . Electrophysiological signs of progressive peripheral polyneuropathy without clinical symptoms were also detected 2-5 years after DLT, however the definitive diagnosis by nerve biopsies couldn't be established [64] .
Recently, cases of sensory neuropathy of the lower limbs without autonomic involvement, occurring as early as 6-7 years after transplant, have been published [65] [66] [67] [68] [69] [70] .
Possible explanations for this accelerated amyloidogenesis are related to age factors since the clinical onset in the cases mentioned varied between 55 and 75 years. However, Obayashi et al. [70] described a case of TTR amyloidosis in a 45-year-old man with primary sclerosing cholangitis that underwent DLT 10 years before. Other potential justifications are surgical trauma, immunosuppression and inflammatory reactions related to graft rejection or reactivation of latent viruses [71] . The clinical onset of TTR amyloidosis in DLT recipients has generally been considered an indication for retransplantation with a non-ATTR liver [61, 62, 64] .
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Its efficacy in halting the disease progression is now starting to be reported, with one case of partial symptomatic recovery [72] . Futurely, pharmacologic treatment may also have a role.
Ericzon et al. [71] advocates that DLT should continue since the ATTR liver can still be an excellent graft when a case by case risk-benefit assessment is done. Other experts [66] [67] [68] 70] reinforce this idea and the need for the future DLT recipient to give a truly informed consent and to be regularly monitored for de novo TTR amyloidosis. Recently, Bolte et al. [69] proposed a scheme for neurologic follow-up of these patients based on periodic assessment of specific scores of peripheral neuropathy, quantitative sensory testing, nerve conduction studies and sural nerve biopsy performed only in patients with ≥2 alterations in the previous tests. According to these findings and the possibility of neuropathy from other etiologies, an estimate of the relative probability of de novo TTR amyloidosis is made.
Multiple Organ Transplantation
According to the FAPWTR, among 2063 reported transplants, there were 46 simultaneous heart-liver transplants and 47 simultaneous liver-kidney transplants. Only 4 were combined heart-liver-kidney transplants.
The first worldwide Combined Heart-Liver Transplantation (CHLT) for ATTR dates back beyond 1993 [73] and the following reports show that all of them were performed in non-TTR V30M cases [74] [75] [76] . This can be explained by their higher and earlier predisposition to cardiomyopathy, that can progress even after successful OLT [30] . Thus they represent the main candidates for this procedure [12, 74, 75] . Outcomes of CHLT have been adversely influenciated by the preoperative clinical status. However, they seem to be encouraging since histological and imagiological evidences of amyloid deposits have not been found yet [74, 75] .
Nevertheless, the hypothesis of progressive neurological disability after CHLT remains [74] .
Combined liver-kidney transplantation (CLKT) is indicated in patients with end-stage renal disease, since renal replacement therapy correlates with poor survival. Moreover, isolated OLT in patients with a preoperative glomerular filtration rate <30mL/min is associated with a significant postoperative deterioration of kidney function [77, 78] . A series of 13 patients with different indications for CLKT, including 3 patients with FAP, reinforced the idea that the liver graft may have a protective immunologic effect on the kidney graft [79] . Lobato et al. [77] reported the absence of proteinuria and a mean serum creatinine in the superior limit of the reference interval after 84 months of follow-up of 6 patients with ATTR V30M submitted to CLKT. These results suggest that CLKT prevents the recurrence of nephropathy, although without histologic evidence of it, but not the progression of polyneuropathy, as expected.
NOVEL THERAPEUTIC APPROACHES
The persistent searching for an ideal therapy to ATTR began too many years ago and it still continues today with a preference towards less invasive options, since the current ones have imperfections or need more time of experience to evaluate the long-term outcomes.
The partial understanding of TTR amyloidogenesis has allowed the development of several potencial new treatments acting in different phases of the process (Table 2 ). Further progresses in that area are expected due to recent success in generation of ATTR-specific induced pluripotent stem cells [80] . Nowadays the most promising drugs seem to be the TTR stabilizing agents. They prevent amyloidogenesis by inhibiting the TTR tetramer dissociation and include the first medical treatment specifically approved to TTR-FAP in Europe in 2011 -tafamidis meglumine. This drug has shown capacity to slow down the progression of early stages of peripheral neuropathy and therefore is formally indicated for patients with the neuropathic form of ATTR in stage I, regardless of the type of mutation [1, 10] . Nevertheless there is evidence that suggests less efficacy in halting neurological dysfunction in non-TTR V30M mutations. Patients with late-onset ATTR V30M involved in a non-randomized controlled trial showed disability progression in 55% of cases and increased Neuropathy Impairment Scores in most of them [9] . Nonsteroidal anti-inflammatory drugs (NSAIDs) are capable of stabilize the TTR tetramer since their structure resembles the one of thyroxine, that is the main responsible for tetramer stabilization. Diflunisal is already in clinical trials with the actual concerns being the therapeutic serum concentrations, the adverse effects profile and its efficacy in other phenotypes of ATTR [1, 10] . An open-label uncontrolled trial was conducted with 13 patients presenting symptomatic and biopsy-proven ATTR cardiomyopathy. They were medicated with diflunisal (250mg bid) for a mean of 10.8 months, during which no significant changes in cardiac structure function and biomarkers were observed. Diflunisal seems to have potential to slow the disease progression, although needs careful renal and hematologic monitoring. These results require confirmation in a randomized placebo-controlled trial [81] .
Several agents are presently under investigation, with some yet restricted to preclinical studies. A recent article about clinical management of ATTR patients expresses the idea that as new effective drugs become available they should be offered to patients meeting their clinical indications, irrespective of liver transplant plans [1] .
DISCUSSION
More than half century after the first description of this progressively incapacitating disease there are still some challenges and unresolved issues, particularly at therapeutic level.
After 23 years of accumulated experience it is well-known that OLT, the first diseasemodifying therapy, allowed a revolution in ATTR treatment, though it has some limitations. In the majority of patients the preexisting symptoms will remain unchanged after OLT and 
TABLES Table 1 -Clinicopathological outcomes
Clinical outcomes Histopathological outcomes
Peripheral neuropathy -Neurologic dysfunction rarely progresses [13, 17, 27, 40, 50] .
-Sensory disturbances and early stages of disease are more likely to improve [6, 17, 35] .
-Recovery of peripheral nerve function is rare [40, 46] .
-Regression of amyloid deposits in peripheral nerves is still uncertain [46] .
Autonomic neuropathy
-Several reports of autonomic disturbances regression, particularly in ATTR V30M [13, 30, 40, 50, 82, 83] .
-Improvement of orthostatic hypotension [27, 43] .
-Decrease of gastrointestinal symptoms and improvement in nutritional status [17, 21, 43, 50, 84] .
-Few reports about bladder and erectile dysfunctions which showed variable outcomes [50, 85] .
-Contradictory histological evidence, favoring the post-transplant persistence of denervation [40] .
Cardiac amyloidosis
-Several reports of cardiomyopathy progression after successful OLT, predominantly but not exclusive for non-ATTR V30M [17, 30, 34, 51, 56, 86] . -Aging also seems to be a risk factor for progression [38] . -Does not prevent life-threatening arrhythmias, which seem more prevalent in ATTR V30M [38, 75, 87] .
-Autopsy findings showed a predominance of wild-type TTR in post-transplant cardiac amyloid deposits [52, 53] .
Renal amyloidosis
-Stabilization of kidney function after an initial deterioration -controversial [35, 38, 88, 89] . -Regression, intensification or onset of proteinuria [85] . -Other factors can contribute to renal impairment -nephrotoxicity of immunosuppressants, kidney damage secondary to neurogenic bladder, diabetes mellitus [6, 35 ].
-The rare histopathological reports suggest that OLT can prevent further progression of kidney amyloidosis [38, 86, 88] . -Biochemical analysis of amyloid kidney deposits supports for de novo amyloidogenesis [52] .
Ocular amyloidosis
-Progression independently of the type of TTR mutation [37] [38] [39] [40] 50, 90] . -Aging is a major determinant of this course [38] .
Leptomeningeal amyloidosis
-One report of unsuccessful OLT in two siblings with ATTR Leu12Pro manifested by grand mal seizures [75] . The most promising agents for halting the relentless progression of ATTR.
Trivalent chromium (Cr
3+
)* Can potentiate the effects of NSAIDs due to its non-competitive action.
TTR T119M monomers* These non-amyloidogenic monomers are incorporated into tetramers making them less amyloidogenic. In vitro studies.
Prevention of amyloid formation
Free radical scavenger therapy (300mg N-acetylcysteine, 300mg α-tocopherol and 500mg vitamin C) Without effect in non-transplanted patients; slight improvement in the nutritional status of transplanted patients.
Immunization with unstable TTR (TTR Y78F)
Clinical application limited by immunization-related inflammation.
Cyclodextrin*
Reduces conformational change of TTR. In preclinical studies. Carvedilol* Decreases amyloid deposits due to antioxidant effect. In preclinical studies.
Dissolution of amyloid aggregates
Lack of in vivo studies. Nephrotoxic.
Doxy-TUDCA (Doxycycline and tauroursodeoxycholic acid)* Seems to stabilize the disease at least during 1 year. Tolerable adverse effects.
Anti-SAP (serum amyloid P component) monoclonal antibodies* Phase 1 study in patients with AA amyloidosis.
Epigallocatechin-3-gallate* In preclinical trials.
# Current available therapies for clinical use. * Therapies with promising future outcomes. Based on Ando et al. [1, 28] , Araki et al. [7] , Hund et al. [10] , Lobato et al. [78] and Adams et al. [9] . a. INTRODUCTION The introduction should give brief background information and state the reasons and purposes behind the study.
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